EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Cost-effectiveness of data driven personalised antibiotic dosing in critically ill patients with sepsis or septic shock

Hana M Broulikova iD, Jacqueline Wallage, Luca Roggeveen, Lucas Fleuren, Tingjie Guo iD, Paul W G Elbers iD, Judith E Bosmans iD

Journal of Clinical Monitoring and Computing · 2025

DOI: 10.1007/s10877-024-01257-9 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Monitoring and Computing, 2025. Verfasst von Hana M Broulikova und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health research institute, Van der Boechorststraat …. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Anti-Bacterial Agents, Shock, Septic, Sepsis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study provides an economic evaluation of bedside, data-driven, and model-informed precision dosing of antibiotics in comparison with usual care among critically ill patients with sepsis or septic shock.

Methods

This economic evaluation was conducted alongside an AutoKinetics randomized controlled trial. Effect measures included quality-adjusted life years (QALYs), mortality and pharmacokinetic target attainment. Costs were measured from a societal perspective. Missing data was multiply imputed, and bootstrapping was used to estimate statistical uncertainty. Differences in effects and costs were estimated using bivariate regression and used to calculate incremental cost-effectiveness ratios.

Results

Patients in the intervention group had higher costs (€42,684 vs. 39,475), lower mortality (42% vs. 49%), more QALYs (0.184 vs. 0.153), and higher pharmacokinetic target attainment (69% vs. 48%). Only the difference for target attainment was found statistically significant. An additional €18,129, €55,576, and €123,493 needs to be invested to attain the targeted plasma levels for one more patient, to save one life and gain one QALY, respectively. The probability of cost-effectiveness for all effect outcomes is below 60% for most acceptable willingness-to-pay thresholds.

Conclusions

Data-driven personalised antibiotic dosing in critically ill patients as implemented in the AutoKinetics trial cannot be recommended for implementation as a cost-effective intervention.

Trial registration

The trial was prospectively registered at Netherlands Trial Register (NTR), NL6501/NTR6689 on 25 August 2017 and at the European Clinical Trials Database (EudraCT), 2017-002478-37 on 6 November 2017.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisAnti-Bacterial AgentsShock, SepticSepsisPrecision MedicineHumansCritical IllnessQuality-Adjusted Life YearsMaleFemaleMiddle AgedAged

Stichwörter der Autor:innen

AntibioticsCost-effectiveness analysisIntensive care softwareModel-informed precision dosingSepsisSeptic shock

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health research institute, Van der Boechorststraat 7, Amsterdam, 1081 BT, the Netherlands. h.m.broulikova@vu.nl.
  • Department of Intensive Care Medicine, Center for Critical Care Computational Intelligence, Amsterdam Cardiovascular Science, Amsterdam Institute for Infection and Immunity, Amsterdam Medical Data Science, Amsterdam Pub…
  • System Pharmacology and Pharmacy, Leiden Academic Center for Drug Research (LACDR), Leiden University, Wassenaarseweg 76, Leiden, 2333 AL, the Netherlands.
  • Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health research institute, Van der Boechorststraat 7, Amsterdam, 1081 BT, the Netherlands.

ORCID-Profile: Hana M Broulikova, Tingjie Guo, Paul W G Elbers, Judith E Bosmans

Förderung

  • ZonMw

Zitieren

APA

Broulikova, H. M., Wallage, J., Roggeveen, L., Fleuren, L., Guo, T., Elbers, P. W. G., & Bosmans, J. E. (2025). Cost-effectiveness of data driven personalised antibiotic dosing in critically ill patients with sepsis or septic shock. Journal of Clinical Monitoring and Computing. https://doi.org/10.1007/s10877-024-01257-9

Vancouver

Broulikova HM, Wallage J, Roggeveen L, Fleuren L, Guo T, Elbers PWG, et al. Cost-effectiveness of data driven personalised antibiotic dosing in critically ill patients with sepsis or septic shock. Journal of Clinical Monitoring and Computing. 2025. doi:10.1007/s10877-024-01257-9

BibTeX
@article{Broulikova2025,
  author = {Broulikova, Hana M and Wallage, Jacqueline and Roggeveen, Luca and Fleuren, Lucas and Guo, Tingjie and Elbers, Paul W G and Bosmans, Judith E},
  title = {Cost-effectiveness of data driven personalised antibiotic dosing in critically ill patients with sepsis or septic shock},
  journal = {Journal of Clinical Monitoring and Computing},
  year = {2025},
  doi = {10.1007/s10877-024-01257-9}
}
Kostenlos starten →